Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
|
This article is part of Pulmonology Advisor‘s coverage of the ACAAI 2018 meeting, taking place in Seattle, Washington. Our staff will report on medical research related to allergy, asthma, and more conducted by experts in the field. Check back regularly for more news from ACAAI 2018. |
SEATTLE — Patients with seasonal allergic rhinitis experienced significant symptom reduction and improved quality of life after implementing olopatadine hydrochloride/mometasone furoate combination nasal spray either once or twice daily, according to a research presented at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology Scientific Meeting, held November 15-19, 2018, in Seattle.
Researchers of this double-blind, phase 2 study randomly assigned patients who were ≥12 years of age to 1 of 5 groups: olopatadine (665 µg)/mometasone (25 µg) twice daily, olopatadine (665 µg)/mometasone (50 µg) once daily, olopatadine (665 µg) once or twice daily, mometasone (25 µg) twice day or mometasone (50 µg) once daily, or placebo. Data were measured using Total Nasal Symptom Scores, Physician-assessed Nasal Symptom Score, and Rhinoconjunctivitis Quality of Life Questionnaire Standardized Activities at baseline and after 14 days of treatment.
Patients who received olopatadine/mometasone either once or twice daily experienced significant improvements in their instantaneous Total Nasal Symptom Scores (P =.005) compared with patients in the placebo group. Statistically significant improvements in physician-assessed nasal symptoms were seen, “further supporting the patient-reported outcomes,” the authors added. Adverse events were reported in 10.8% of the olopatadine/mometasone twice daily group, in 9.5% of the olopatadine/mometasone once daily group, and in 8.2% of the placebo group.
The researchers concluded that taking olopatadine/mometasone either once or twice daily “provided statistically significant improvements in both [seasonal allergic rhinitis] nasal symptoms and [quality of life] vs placebo.”
Disclosures: This study was supported by the Glenmark Pharmaceuticals Ltd. India.
|
Visit Pulmonology Advisor‘s conference section for continuous coverage from ACAAI 2018 |
Reference
Andrews C, Mohar D, Jacobs R, Tantry S. Olopatadine/mometasone combination nasal spray effectively improves seasonal allergic rhinitis nasal symptoms and quality of life. Presented at: the Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology; November 15-19, 2018; Seattle, WA. Poster P454.
